<DOC>
	<DOCNO>NCT00337129</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , E7389 , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well E7389 work treat patient metastatic recurrent head neck cancer .</brief_summary>
	<brief_title>S0618 E7389 Treating Patients With Metastatic Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate response probability ( confirm , complete , partial response ) patient metastatic recurrent squamous cell carcinoma head neck treat E7389 . - Estimate progression-free overall survival probability patient . - Evaluate qualitative quantitative toxicity treatment regimen . OUTLINE : This multicenter study . Patients receive E7389 IV day 1 8 . Courses repeat every 21 day absence unacceptable toxicity disease progression . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma head neck ( SCCHN ) Disease either metastatic diagnosis persist , metastasize , recur definitive surgery and/or radiotherapy Not amenable surgical resection salvage therapy No newly diagnose nonmetastatic disease No salivary nasopharyngeal primary disease Patients fail primary surgery alone , disease salvageable radiation chemoradiation , eligible Measurable disease Measurable disease within previous radiotherapy port must demonstrate clearly progressive disease No active prior CNS metastasis PATIENT CHARACTERISTICS : Zubrod performance status 01 Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 2 time upper limit normal ( ULN ) SGOT SGPT ≤ 2 time ULN Creatinine ≤ 2 time ULN Not pregnant nursing Fertile patient must use effective contraception No known HIV positivity No prior malignancy except follow : Adequately treat basal cell squamous cell skin cancer In situ cervical cancer Adequately treat stage I II cancer currently complete remission Any cancer patient disease free ≥ 5 year PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy recurrent newly diagnose metastatic disease At least 6 month since prior induction adjuvant chemotherapy patient relapse receive therapy No 1 prior induction adjuvant regimen ( may include taxane ) More 2 week since prior biologic therapy ( i.e. , epidermal growth factor inhibitor vascular endothelial growth factor inhibitor ) More 28 day since prior radiotherapy recover More 28 day since prior surgery recover No concurrent therapy ( i.e. , radiotherapy , chemotherapy , immunotherapy , biologic therapy , gene therapy ) SCCHN No concurrent combination antiretroviral therapy HIVpositive patient No concurrent prophylactic colonystimulating factor course 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
</DOC>